To enhance efficacy of cancer immunotherapy, we must discover how adenocarcinomas resist PD-1-directed therapy. In a mouse model of pancreatic ductal adenocarcinoma (PDA), it has been shown that inhibiting the chemokine receptor, CXCR4, overcomes resistance to anti-PD-L1. Here, we show that the PDA cancer cells exhibit an extracellular, covalent complex between keratin 19 (KRT19) and CXCL12, the ligand for CXCR4, which is produced by the cancer-associated fibroblast (CAF). PDA tumors containing gene-edited cancer cells that cannot express KRT19 or transglutaminase-2 (TGM2) lack the CXCL12-coat, are infiltrated with T cells, and regress during treatment of tumor-bearing mice with anti-PD-1. Therefore, TGM2 of pancreatic cancer cells enables their escape from immune attack by capturing the immune suppressive chemokine of the CAF. These findings may explain the resistance to immunotherapy of multiple human adenocarcinomas in which we find this CXCL12-coat.
The trafficking of immune cells into and within tissues is regulated by their chemokine receptors responding to chemokines produced at these sites. The complexity of this system, which includes more than 50 chemokines and chemokine receptors, enables the assembly of the different populations of immune cells that can mediate the diversity of responses that characterize the immune system (10) . A relevant interaction between the cancer cell and this chemokine/chemokine receptor system was suggested by the finding that CXCL12, which is produced by CAFs (11, 12) , appeared to "coat" cancer cells in a mouse model of PDA (13) . Moreover, CXCL12 was shown to mediate tumoral immune suppression in mouse PDA when conditionally depleting CAFs or inhibiting CXCR4, the CXCL12 receptor, increased T cell infiltration, controlled tumor growth, and uncovered sensitivity to inhibition of the PD-1 checkpoint (13, 14) . Here, we examine how mouse PDA cancer cells capture CXCL12 and the role of the resulting CXCL12-coat in suppressing the intra-tumoral trafficking of T cells and the anti-tumor effects of anti-PD-1 therapy.
We assessed whether the finding of the CXCL12-coat in mouse PDA was relevant to human cancer. Fluorescently labeled anti-CXCL12 antibodies stained the KRT19-expressing cells in sections of human pancreatic, colon, breast, and bladder cancers, respectively ( Fig. 1A) , all tumors that have been reported to exclude T cells, and other KRT19-expressing adenocarcinomas that resist PD-1-directed immunotherapy (15, 16) (Fig. S1A ). Melanoma cells, which do not express KRT19, are not coated with CXCL12 (Fig. S1A) . The KRT19-expressing cancer cells in mouse autochthonous and subcutaneous PDA tumors were also stained with anti-CXCL12 antibody, and T cells were seen in the stromal regions of the tumors but not in cancer cell nests ( Fig. 1B, C) . Cxcl12 mRNA was detected in the PDGFRα-expressing, fibroblastic stromal cells by fluorescent in situ hybridization (FISH), but not in the KRT19-expressing cancer cells of these tumors (Fig. S1B) , demonstrating that the cancer cell-associated CXCL12 was derived from the CAFs. Confocal microscopy of individual PDA cells that were not permeabilized in mouse tumors showed co-localization of CXCL12 and KRT19 to the periphery of the cells (Fig. 1D ). We confirmed the extracellular location of KRT19 and CXCL12 by FACS analysis of intact cancer cells released from subcutaneous PDA tumors that had been stained with anti-KRT19 and anti-CXCL12 antibodies (Fig. S1C ).
To examine further the association of CXCL12 with the PDA cells, we excised subcutaneous PDA tumors, treated them sequentially with NP-40, sodium deoxycholate (DOC), DNase, and sodium dodecyl sulfate (SDS), and analyzed the lysates by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting with anti-KRT19 and anti-CXCL12 antibodies. CXCL12 was detected only in the tumor lysate obtained with SDS, with an apparent molecular weight of ~52 kD, instead of its native molecular weight of 9-11 kD ( Fig. 1E ). KRT19 also was released by SDS-treatment of the PDA tumors, with the major band having the ~44 kD molecular weight of the native protein and two minor bands with higher apparent molecular weight. We assessed the possibility that the high molecular weight forms of CXCL12 and KRT19 represented a complex by subjecting the SDS-lysate to immunoprecipitation with anti-CXCL12 antibody, and analyzing the precipitated proteins by SDS-PAGE followed by immunoblotting. A single band was detected with anti-KRT19 antibody that co-migrated with the high molecular weight form of CXCL12 ( Fig. 1F ), demonstrating a covalent association between the two proteins on the surface of the PDA cells.
The formation of a complex between CXCL12 and only KRT19 suggested that this epithelial cell protein serves as an obligatory acceptor for CXCL12. We assessed this hypothesis by CRISPR/Cas9-editing the Krt19 gene in the mouse PDA line and forming subcutaneous tumors with the edited PDA cells ( Fig. 2A; Fig. S2A ). The Krt19-edited PDA cells, which were identified by their expression of KRT20, lacked the CXCL12-coat ( Fig. 2B; Fig. S2B ). The tumors also did not exclude T cells ( Fig. 2B; Fig. S3A ) and grew more slowly than the tumors formed with control PDA cells (Fig. 2C ). The activation of the infiltrating T cells was inferred by their increased expression of the effector genes, IFN-, perforin and granzyme A ( Fig. 2D; Fig.  S3B ). When subcutaneous tumors were formed with Krt19-edited PDA cells in which KRT19 expression had been rescued, both the assembly of the CXCL12-coat and the exclusion of T cells were again observed (Fig. S4 ).
The stability of the CXCL12-KRT19 complex in the presence of SDS suggested a covalent linkage between the two proteins. TGM2 forms inter-molecular, isopeptide bonds between glutamines and the γ-amino groups of lysines (17) , and is expressed by epithelial cells and myelomonocytic cells. We anticipated that cancer cell-derived TGM2 would be the relevant source of this enzyme because the presence of infiltrating myelomonocytic cells would be mutually exclusive with the formation of the CXCL12-coat. Therefore, we CRISPR/Cas9-edited Tgm2 in PDA cancer cells and induced subcutaneous tumors with the modified cells ( Fig. 3A ; Fig. S5 ). In some areas of these tumors, the TGM2-deficient PDA cancer cells lacked CXCL12staining, whilst in other areas, cancer cells had CXCL12-staining, but this was significantly less than that of cancer cells expressing TGM2 ( Fig. 3A-D) . Therefore, the absence of TGM2expression in PDA cells alters the fixed, stoichiometric relationship between KRT19 and CXCL12 that is observed in the tumors formed with unedited PDA cells. This less effective CXCL12-coating of Tgm2-edited cancer cells, which may reflect the activity of TGM2 from infiltrating myelomonocytic cells, however, was not sufficient to prevent the intra-tumoral accumulation of activated T cells when we quantified the T cell number and gene expression in CXCL12-low and CXCL12-negative areas ( Fig. 3E , F; Fig S6) . Furthermore, the T cell density in these two areas of the Tgm2-edited tumors was similar to that of the KRT19-deficient PDA tumors (Fig. 3F ). The observation that the Tgm2-edited PDA tumors and Krt19-edited PDA tumors have similar T cell infiltration and slower growth rates ( Fig. 3G ) suggests that only the CXCL12-coat assembled by TGM2 expressed by the PDA cell has an immune modulatory effect.
We determined whether the presence of the CXCL12-coat on PDA cancer cells was the basis for the resistance of PDA tumors to antagonists of the PD-1 checkpoint. Mice with established, subcutaneous tumors formed with non-edited PDA cells, Krt19-edited PDA cells, and Tgm2edited PDA cells, respectively, were treated with control IgG or anti-PD-1 antibody for one week, avoiding the confounding effects of neutralizing anti-rat antibodies ( Fig. S7 ). Anti-PD-1 antibody treatment caused regression of tumors containing either Krt19-or Tgm2-edited PDA cells ( Fig. 4A ), but had no effect on control tumors composed of PDA cells having the CXCL12coat. This heightened intra-tumoral immune reaction occurring when anti-PD-1 was combined with cancer cells lacking the CXCL12-coat is also demonstrated by the enhanced expression of genes indicating the accumulation of activated CD8 + T cells (Fig. S8A ). The increased Cxcl12 mRNA in these tumors may be an adaptive response of the CAF to this intensified immune reaction ( Fig. S8B ).
Treatment of hepatic metastasis presents the main therapeutic challenge in the management of patients with PDA. To model this clinical condition, we injected control and Krt19-edited, luciferase-expressing PDA cells into the portal veins of mice. The KRT20 + PDA cells in metastatic lesions containing control PDA cells exhibited CXCL12-coats and excluded T cells, as previously shown (18) . In contrast, Krt19-edited PDA cells in metastatic lesions lacked the CXCL12-coat, and cancer cell nests were infiltrated with T cells (Fig. S9A, B ). Both types of metastases contained CAFs co-expressing Cxcl12 and Pdgfa (Fig. S9C, D) . The infiltrating CD8 + T cells in metastases containing KRT19-deficient cancer cells had elevated mRNA levels of Ifng, Gzma, and Prf1 (Fig. S10A ), to which the increased expression of Cxcl9, Cxcl10 and Cxcr3 may have contributed ( Fig. S10B ). Intra-tumoral T cell proliferation also occurred, as suggested by the finding of Ki67-expressing CD8 + T cells (Fig. S11 ). The mRNA levels of the CAF markers, FAP and CXCL12, were not decreased ( Fig. S10B ), constituting further evidence that the availability of CXCL12 was not a contributing factor to the absence of the CXCL12-coat on the KRT19-deficient PDA cells. Finally, and most importantly, treatment of mice with anti-PD-1 prevented the growth of hepatic metastases formed with PDA cells lacking KRT19 and the CXCL12-coat. Metastases containing control PDA cells having the CXCL12-coat did not respond to this immunotherapy ( Fig. 4B; Fig. S12 ).
These studies demonstrate that the intra-tumoral accumulation of T cells is regulated by the capacity of cancer cells to capture CXCL12 from the tumor microenvironment. The cancer cell component of this response depends on the expression of KRT19 and TGM2. The translational relevance of these experiments is demonstrated by finding the CXCL12-coat on multiple human carcinomas, and by the reduced survival of patients with pancreatic cancer and high intratumoral KRT19 or TGM2 expression ( Fig. S13 ). It is probable that this biochemical coating mechanism evolved to protect normal epithelial cells from immune attack by appropriating the immune suppressive effects of CXCL12, a product of a fibroblastic cell type that resides in normal tissues (19) and accumulates in inflammatory lesions (20) . The critical cellular event may be the coordinated secretion of KRT19 and TGM2 by an unconventional pathway, which is necessitated by the absence in both proteins of a signal peptide. Although the extracellular secretion of these proteins has been demonstrated (21, 22) , the stimulus has not been identified. We also have not explained how cancer cell-associated CXCL12 suppresses the intra-tumoral trafficking of T cells, but the mechanism must involve its receptor, CXCR4 (13) , and may relate to the reported capacity of high concentration CXCL12 to cause chemorepulsion of T cells in vitro (23) . The current study identifies TGM2 as a potential combination therapy target in immunotherapy trials, but it particularly emphasizes the urgent need to assess the combined therapeutic efficacy of CXCR4 inhibitors with blockade of the PD-1/PDL1 axis in patients with PDA. 
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Materials and Methods
Human Tumor Arrays
Formalin fixed paraffin embedded (FFPE) human tumor arrays for pancreas cancer (PA501a), colon cancer (BC05021a), breast cancer (BC08013c), bladder cancer (BC12011d), melanoma (ME483a) and frozen multiple organ tumor/tissue arrays (FMC282e and FMO401) were purchased from US Biomax.
Animals
Male C57Bl/6 mice of 6 weeks old were purchased from The Jackson Laboratory. After receiving, the mice were housed in helicobacter free room for 2 weeks before experiment. All experimental procedures conducted on mouse were approved by the Cold Spring Harbor Laboratory (CSHL) Institutional Animal Care and Use Committee (IACUC). And the NIH "Guide for the Care and Use of Laboratory Animals" was complied with in animal studies.
CRISPR editing and lentivirus
The control CRISPR guide (sgScramble: GCTTAGTTACGCGTGGACGA (24)) and the guides targeting to mouse Krt19 gene (sgKRT19-1: CACAGGAAATTACTGCCCTG; sgKRT19-2: TAGTGGTTGTAATCTCGGGA; sgKRT19-3: CGGAGGACGAGGTCACGAAG) or mouse Tgm2 gene (sgTGM2-1: GAATATGTCCTTACGCAACA; sgTGM2-2: GTCCTGTTGGTCCAGCACTG; sgTGM2-3: TTGACCTCGGCAAACACGAA) were cloned into the lentiCRISPR-v2 plasmid (Addgene, 52961) and sequencing validated. The lentivirus was produced by co-transfecting HEK293T cells with the guide containing lentiCRISPR-v2 plasmid together with the lentivirus packing plasmid psPAX2 (Addgene, 12260) and the envelop expressing plasmid pMD2.G (Addgene, 12259).
Cell Lines
Mouse pancreas ductal adenocarcinoma (PDA) cancer cell line 1242 which was derived from KPC (LSL-Kras G12D/+ ; LSL-Trp53 R172H/+ ; Pdx1-Cre) mouse tumor (25) is a gift from D. Tuveson lab. To generate sgScramble, sgKRT19 and sgTGM2 cell lines, 1242 cells were transduced with lentivirus expressing SpCas9 and specific CRISPR guide. The transduced cells were directly selected with 1 μg/ml puromycin (Sigma, P8833) for polyclonal stable cell lines. The single cell clones were generated by limited dilution. Most experiments were done with the single cell clones otherwise indicated. To rescue KRT19 expression in the Krt19-edited cancer cells which was achieved by transduction with the lentivirus containing the sgKRT19-1 guide, the single cell clone was further transduced with lentivirus expressing mouse KRT19 with four synonymous mutations at the guide targeting site (Fig. S4A ). To facilitate tumor imaging in vivo for hepatic metastasis, the sgScramble and sgKRT19 cell lines were further introduced with lentiviral plasmid expressing firefly luciferase and GFP which are linked by 2A peptide. The luciferase/GFP transduced cells were sorted by FACS. All the cell lines were cultured in DMEM medium (Cellgro, 10-013-CV) supplemented with 10% FBS (Seradigm, 1500-500), 100 units/ml penicillin and 100 μg/ml streptomycin.
Mouse studies
For subcutaneous tumors, 2.5×10 5 cells, or otherwise indicated, were injected at right flank of mouse. Tumor volume was measured with caliper every two days and calculated according to the formula V = (L×W 2 )/2. Mice developed with tumor associated ulcer before end of the experiment were ruled out, and the ulcerated tumors were not included in any analysis. For hepatic metastasis model, 2.5×10 4 or 1.0×10 5 luciferase expressing cells were injected through portal vein. Tumor size was monitored through bioluminescence imaging every 3 or 4 days. Basically, 150 μl of 30 mg/ml D-Luciferin (Perkin-Elmer, 122799-10) was administered through intraperitoneal injection and mice were imaged with the IVIS Spectrum in vivo Imaging System. For tumor treatment, 200 μg isotype IgG (BioXcell, BP0089) or Rat anti-mouse PD-1 antibody (BioXcell, BP0273) was given through intraperitoneal injection on indicated days. T cell depletion was done by intraperitoneal injection of 200 μg anti-CD4 (BioXcell, BP0003) and anti-CD8 (BioXcell, BP0061) antibodies twice a week.
Immunofluorescence
Mouse tumors were embedded in Tissue-Tek OCT compound (Sakura, 4583) and freshly frozen on dry ice. In the case of hepatic metastatic tumors, the whole livers were perfused through portal vein with cold PBS before freezing. The embedded tumors were sectioned at 10μm for staining. For Human FFPE tumor arrays, the slides were deparaffinized in Xylene for three times (5 min each) followed by sequential rehydration treatments in 100% ethanol (5 min, 3 times), 95% ethanol (10 min, twice), 70% ethanol (10 min, twice), 50% ethanol (10 min, twice), and water (5 min, twice). After rehydration, antigen retrieval was conducted by boiling the sample in 10mM Tris-HCl (pH 8.8) plus 1mM EDTA for 10 min. Then, keep the sample slides in the boiled buffer and cool down on bench top for 30 min followed by wash in water for 5 min, twice.
To stain tumor sections, the samples were fixed with freshly prepared PLP buffer (100 mM phosphate buffer, pH 7.4, 80 mM L-lysin, 10 mM NaIO 4 , and 4% paraformaldehyde) for 10 min at room temperature. After wash with PBS, hydrophobic barrier was drawn around the tumor slice with ImmEdge PAP pen (Vector Laboratories, H-4000). The sections were then permeabilized with 0.2% TritonX-100 in PBS for 15 min followed by blocking with 1% BSA (Calbiochem, 2930) plus 10% normal goat serum (Thermo, 16210064) in PBS for 1 hour at room temperature. Non-conjugated primary antibodies (Table S1 ) were incubated at 4°C overnight. Fluorophore conjugated secondary antibodies were incubated at room temperature for 1 hour. And fluorophore conjugated primary antibodies (Table S1 ) were incubated at room temperature for 2 hours. Nuclei were stained with DAPI (Thermo, R37606) at room temperature for 10min. In between each steps, sections were washed with 0.05% Tween-20 in PBS for 5min twice and PBS for 5 min once. Afterwards, tumor sections were mounted with mounting medium (Thermo, P36961). For the staining of the thick (30 μm) non-permeabilized section (Fig. 1C) , TritonX-100 was not included. Images were acquired on Leica SP8 confocal microscope or ZEISS Observer microscope and analyzed with ImageJ software.
Tumor Protein Extraction
Tumor pieces of about 100 mg were used for protein extraction. Freshly dissected tumor piece or the tumor piece that was previously flash-frozen in liquid nitrogen and stored in -80°C was homogenized in 1 ml ice cold IP buffer (75 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM DTT, 10% Glycerol, protease inhibitor cocktail (Thermo, 78437)) plus 1% NP-40. After removal of remaining tissue particles by flowing through the Pierce Tissue Strainer (Thermo, 87791), the homogenized tissue was sequentially extracted: (1) Re-suspend and incubate at 4°C on rotator for 10min followed by centrifugation at 4,000g for 5 min. Save the supernatant as "NP-40 extract". Repeat to wash the pellet; (2) Re-suspend the pellet in 250 μl IP buffer plus 0.1% sodium deoxycholate (DOC) and incubate at 4°C on rotator for 30 min followed by centrifugation at 6,000g for 5 min. Save the supernatant as "DOC extract". Repeat to wash the pellet; (3) Re-suspend the pellet in 200 μl IP buffer plus 5 mM Ca 2 Cl and 3,000 units/ml micrococcal nuclease (Thermo, 88216) and incubate at room temperature for 30 min followed by centrifugation at 16,000g for 5 min. Save the supernatant as "DNase extract". Repeat to wash the pellet; (4) Re-suspend the pellet in 150 μl IP buffer plus 1% SDS and incubate at room temperature for 10 min followed by centrifugation at 16,000g for 5 min. Keep the supernatant as "SDS extract". Protein concentration was measured with protein assay kit (BioRad, 5000112) and 1 μg of each fraction that was boiled in Laemmli sample buffer was applied to SDS-PAGE gel for western blot. The KRT19 antibody TROMA-III, which was deposited by Kemler R. to Developmental Studies Hybridoma Bank (DSHB), was used for western blot.
Immunoprecipitation SDS in the cytoskeleton fraction was removed with the Pierce Detergent Removal Spin Column (Thermo, 87777). For immunoprecipitation, 100 μg of the protein extract was diluted in 500 μl IP buffer containing 1% BSA (Calbiochem, 2930). To prevent self-assembly of cytokeratin proteins, 0.1% SDS was added. The mixture was pre-cleared by centrifugation at 16,000g for 10 min and the supernatant was transferred in to a new tube. Then, 5 μg Rabbit isotype IgG (Thermo, 10500C) or Rabbit anti-CXCL12 antibody (LSBio, LS-C48888) was added in to the solution followed by incubation on rotor at 4°C overnight. At the same time, protein G agarose beads (Cell signaling, 37478) were also incubated in IP buffer containing 1% BSA overnight. After overnight incubation, 20 μl pure protein G resins (or 40 μl 50% slurry) were added directly to the protein/IgG solution and incubate for another 2 hours at 4°C. Following 3 times wash with IP buffer containing 0.1% SDS, the resins were boiled in 100 μl Laemmli sample buffer and 10 μl sample was applied to SDS-PAGE gel for western blot where Veriblot for IP detection reagent HRP (Abcam, ab131366) was used.
RNA FISH
RNA FISH was done with fresh frozen tumor samples according to user manual of RNAScope Fluorescent Multiplex Reagent kit (ACDBio, 320850). RNAScope probes for mouse Cxcl12 (422711), Pdgfra (480661-C2), and Krt19 (402941-C3) were used in this study. Images were acquired on Leica SP8 confocal microscope and analyzed with ImageJ.
Flow Cytometry
Freshly resected tumors were minced and digested in complete DMEM cell culture medium containing 250 μg/ml Collagenase D (Sigma, 11088858001), 50 μg/ml Liberase DL (Sigma, 05466202001) and 20 μg/ml DNase I (Sigma, 10104159001) at 37°C for 45 min, shaking. Following lysis of red blood cells in RBC lysis buffer (155 mM NH4Cl, 12 mM NaHCO3 and 0.1 mM EDTA), cells were flown through 70 μm cell strainer and re-suspend in DMEM medium containing 50 μg/ml DNase I to digest released DNA from RBC cells. After incubation at room temperature for 15 min, the cells were washed and re-suspended in FACS buffer (PBS, 2% FBS and 20 mM HEPES, pH 7.4). For staining, the cells were firstly blocked with Rat anti-mouse CD16/CD32 antibody (BioLegend, 101302) in FACS buffer, shaking at 4°C for 30 min. Then, fluorophore conjugated antibodies (Table S1 ) were added and incubated for another 30 min in the dark, followed by two times wash in FACS buffer. Calcein violet 450 AM (Thermo, 65-0854-39) or DAPI (Thermo, R37606) was used for live cell gating. Data was acquired, in the CSHL Flow Cytometry Shared Resource, with BD LSRForsseta cell analyzer equipped with Diva software 6.0 and was further analyzed with FlowJo.
RT-qPCR
Tumor samples of about 30mg were flash-frozen in liquid nitrogen and stored in -80°C. Total RNA was extracted with RNeasy mini kit (Qiagen, 74106) according to the manual. To make the cDNA library, 1 μg total RNA was reverse transcribed with Taqman Reverse Transcription Kit (Thermo, N8080234), using oligo d(T)s. cDNA library was then diluted in 100 μl nuclease free water. For RT-qPCR, 5 μl diluted cDNA library was mixed in 384 well plate with specific Taqman probes (Table S2 ) and Taqman Universal Master Mix II (Thermo, 4440040) to make 10 μl reaction system. The qPCR were run in QuantStudio 6. All the gene expression values were normalized to Tbp. Mouse anti-rat IgG in blood serum of the mice receiving the anti-PD-1 antibody was measured by means of ELISA. 200 μg anti-PD-1 antibody was administered by intra-peritoneal injections at indicated days (red arrows).
Fig. S8: Gene expression analysis of the subcutaneous PDA tumors treated with anti-PD-1.
(A-B) The tumor bearing mice were treated with 200 μg isotype IgG or anti-PD-1 antibody at day 13 and day 15 after PDA cancer cell inoculation. Mice were sacrificed at day17, and samples of the tumors were obtained. The mRNA levels of each gene in the tumor samples were measured by means of RT-qPCR. The expression of each gene in sgScramble tumors from mice that had been treated with isotype IgG were normalized to 1. Mean ± SEM; * p<0.05, ** p<0.01, Student's t test. 
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